Great observations, kgb03.14!
With your unique dot connecting skills, we are rapidly moving ahead towards an ultimate buyout. It would be helpful to add another similarity between AFMD and ADXS -- remember an AXAL submission for a conditional approval in EU? I am sure that ADXS pulled that application not because they had incomplete data, but because Roche's Genentech decided to postpone that approval until after the buyout. There were threatened by the slam dunk possibility of approval of AXAL for cervical cancer in Europe threatening their core business model. Thus, one of the most powerful EU pharmas decided to force Advaxis for a temporary withdrawal so that they have sufficient time to accumulate shares. The puzzle is almost solved!
Add to this theory (almost validated though!) that Advaxis filed another Form-3 and removed ATM clause from it. Also, Ken did not even bother to create his new ADXS twitter account knowing very well that they would be bought out. All pieces of this huge puzzle now started to fit into a big, nice picture. What do I see on it? A $5,125,793,486.12 check written by Roche.
@wmtgreeter
News 
Market Data 
Discover 
AI
